AI Research for Pharma

Pharma commercial teams operate under a specific constraint: the decisions are high-stakes, the timelines are rigid, and the people whose opinions matter most are nearly impossible to get on the phone.

A KOL advisory board costs $50,000-100,000 and takes months to organize. Patient panels require IRB coordination. Payer research is a specialized discipline with a two-month lead time. And the launch window doesn't move because your research isn't ready.

AI simulation gives pharma teams a way to pressure-test their commercial strategy continuously, not just when the research budget and timeline align.

Drug Launch Positioning

The most expensive mistake in pharma is launching with the wrong positioning. You get one shot at first impressions with prescribers, and repositioning after launch is slow and costly.

Traditional launch research follows a predictable pattern: qual with HCPs, message testing, conjoint analysis, maybe an ATU study. It works, but it's sequential, expensive, and produces results in batches rather than continuously.

With Minds, commercial teams can build AI personas of their target prescribers and test positioning concepts iteratively. Build the skeptical community oncologist who's seen three new entrants in this class. Build the academic KOL who cares about mechanism of action data. Build the formulary committee member who's focused on budget impact.

Ask each of them: "Here's our positioning. What's your first reaction?" Then iterate. Change the emphasis. Lead with efficacy vs. safety vs. convenience. Find out which framing resonates before you lock the detail aid.

KOL Simulation

KOL management is part science, part relationship management. The challenge is that you can only have so many conversations with real KOLs before you're using up goodwill that's better spent on actual advisory work.

AI simulation lets you prepare for KOL interactions by stress-testing your arguments first:

Pre-advisory board prep. Build personas of your advisory board members based on their publication record, known positions, and therapeutic area focus. Run your discussion guide against them. Find out which questions will generate useful debate and which will fall flat.

Objection mapping. Build the toughest critic in your therapeutic area. Present your data. See what they push back on. Go into the real meeting prepared.

Competitive intelligence. Build a persona of a KOL who champions a competitor's product. Understand their argument structure. Prepare counter-positioning.

The output isn't a substitute for real KOL relationships. It's preparation that makes real interactions more productive.

Patient Journey Mapping

Traditional patient journey research is a heavyweight project: recruit patients, conduct depth interviews, synthesize findings, present to the team. Minimum 6-8 weeks, $40,000-80,000.

AI simulation compresses the initial exploration. Build patient personas at each journey stage — pre-diagnosis, diagnosis, first treatment, treatment failure, switching, long-term management. Map their emotional states, information needs, and decision triggers.

The output is a hypothesis-rich journey map that tells you where to focus your real-world research. Instead of spending the first four interviews figuring out which journey stages matter, you go in already knowing — and spend those interviews on depth.

Particularly useful for:

• Rare diseases where patients are extremely hard to recruit
• Chronic conditions where the journey spans years and traditional research only captures snapshots
• Oncology where patient willingness to participate in research varies dramatically by stage

Formulary Committee Simulation

This is where simulation gets genuinely strategic. Formulary committees are essentially impossible to research directly — you can't convene one for a research study, and individual P&T members rarely participate in market research.

But you can build AI personas based on formulary committee archetypes: the cost-focused pharmacy director, the clinically-minded physician member, the outcomes-oriented medical director. Present your value story. See where it breaks.

Budget impact testing. "Here's our cost-effectiveness argument. What questions would you ask?"

Competitive positioning. "Three products in this class are on formulary. Here's why ours should be added. What's your reaction?"

Access strategy refinement. Test different restriction levels, step therapy positioning, and prior authorization criteria against simulated committee members.

The simulation won't predict actual formulary decisions. But it will surface the objections and questions you need to prepare for.

Integrating with Traditional Pharma Research

AI simulation works best as a complement to the traditional pharma research stack, not a replacement:

The ROI is clearest in two areas: faster iteration cycles (test five positioning concepts in a week instead of testing two in a month) and broader stakeholder coverage (simulate payers, patients, and prescribers simultaneously instead of sequentially).

Compliance and Transparency

Pharma teams need to be clear about what AI simulation is and isn't:

• It's a hypothesis generation and testing tool, not evidence generation
• Simulated KOL opinions should never be attributed to real individuals
• Insights from simulation should be validated with real-world research before informing regulatory or promotional claims
• Minds offers GDPR-compliant data handling with DPA available

The companies using this well treat simulation as their continuous intelligence layer — always running, always testing, always refining — while traditional research handles the moments that require real-world validation.

Build your pharma research panel →